A human adenovirus encoding IFN-γ can transduce Tasmanian devil facial tumour cells and upregulate MHC-I
journal contributionposted on 2023-05-21, 15:04 authored by Kayigwe, AN, Jocelyn DarbyJocelyn Darby, Alan LyonsAlan Lyons, Amanda PatchettAmanda Patchett, Lisowski, L, Guei-Sheung LiuGuei-Sheung Liu, Andrew FliesAndrew Flies
The devil facial tumour disease (DFTD) has led to a massive decline in the wild Tasmanian devil (Sarcophilus harrisii) population. The disease is caused by two independent devil facial tumours (DFT1 and DFT2). These transmissible cancers have a mortality rate of nearly 100 %. An adenoviral vector-based vaccine has been proposed as a conservation strategy for the Tasmanian devil. This study aimed to determine if a human adenovirus serotype 5 could express functional transgenes in devil cells. As DFT1 cells do not constitutively express major histocompatibility complex class I (MHC-I), we developed a replication-deficient adenoviral vector that encodes devil interferon gamma (IFN-γ) fused to a fluorescent protein reporter. Our results show that adenoviral-expressed IFN-γ was able to stimulate upregulation of beta-2 microglobulin, a component of MHC-I, on DFT1, DFT2 and devil fibroblast cell lines. This work suggests that human adenoviruses can serve as a vaccine platform for devils and potentially other marsupials.
Australian Research Council
Publication titleJournal of General Virology
Department/SchoolMenzies Institute for Medical Research
PublisherSoc General Microbiology
Place of publicationMarlborough House, Basingstoke Rd, Spencers Woods, Reading, England, Berks, Rg7 1Ag
Rights statement© 2022. The Authors. This article was made open-access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution. This article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.